International Center of Molecular Physiology NASU, Kyiv, Ukraine.
Br J Pharmacol. 2011 Feb;162(3):701-11. doi: 10.1111/j.1476-5381.2010.01072.x.
A class of drugs known as K(ATP) -channel openers induce cardioprotection. This study examined the effects of the novel K(ATP) -channel opener, the fluorine-containing pinacidil derivative, flocalin, on cardiac-specific K(ATP) -channels, excitability of native cardiac myocytes and on the ischaemic heart.
The action of flocalin was investigated on: (i) membrane currents through cardiac-specific K(ATP) -channels (I(KATP) ) formed by K(IR) 6.2/SUR2A heterologously expressed in HEK-293 cells (HEK-293(₆.₂/₂A) ); (ii) excitability and intracellular Ca²(+) (Ca²(+) ) transients of cultured rat neonatal cardiac myocytes; and (iii) functional and ultrastructural characteristics of isolated guinea-pig hearts subjected to ischaemia-reperfusion.
Flocalin concentration-dependently activated a glibenclamide-sensitive I(KATP) in HEK-293(₆.₂/₂A) cells with an EC₅₀= 8.1 ± 0.4 µM. In cardiac myocytes, flocalin (5 µM) hyperpolarized resting potential by 3-5 mV, markedly shortened action potential duration, reduced the amplitude of Ca²(+) transients by 2-3-fold and suppressed contraction. The magnitude and extent of reversibility of these effects depended on the type of cardiac myocytes. In isolated hearts, perfusion with 5 µmol·L⁻¹ flocalin, before inducing ischaemia, facilitated restoration of contraction during reperfusion, decreased the number of extrasystoles, prevented the appearance of coronary vasoconstriction and reduced damage to the cardiac tissue at the ultrastructural level (state of myofibrils, membrane integrity, mitochondrial cristae structure).
Flocalin induced potent cardioprotection by activating cardiac-type K(ATP) -channels with all the benefits of the presence of fluorine group in the drug structure: higher lipophilicity, decreased toxicity, resistance to oxidation and thermal degradation, decreased metabolism in the organism and prolonged therapeutic action.
一类被称为 K(ATP)通道开放剂的药物可诱导心脏保护作用。本研究探讨了新型 K(ATP)通道开放剂氟代皮拉地平衍生物 flocalin 对心脏特异性 K(ATP)通道、原生心肌细胞兴奋性以及缺血心脏的影响。
研究了 flocalin 对以下方面的作用:(i)通过在 HEK-293 细胞(HEK-293(₆.₂/₂A))中异源表达的 K(IR) 6.2/SUR2A 形成的心脏特异性 K(ATP)通道(I(KATP))的膜电流;(ii)培养的大鼠新生心肌细胞的兴奋性和细胞内 Ca²⁺(Ca²⁺)瞬变;以及(iii)在缺血再灌注过程中分离的豚鼠心脏的功能和超微结构特征。
氟代皮拉地平浓度依赖性地激活了 HEK-293(₆.₂/₂A)细胞中格列本脲敏感的 I(KATP),其 EC₅₀值为 8.1±0.4µM。在心肌细胞中,flocalin(5µM)将静息电位超极化 3-5mV,明显缩短动作电位持续时间,将Ca²⁺瞬变的幅度降低 2-3 倍,并抑制收缩。这些效应的幅度和可逆性取决于心肌细胞的类型。在分离的心脏中,在诱导缺血之前用 5µmol·L⁻¹ flocalin 灌注可促进再灌注期间收缩的恢复,减少室性早搏的数量,防止冠状动脉收缩,并减少超微结构水平的心脏组织损伤(肌原纤维状态、膜完整性、线粒体嵴结构)。
氟代皮拉地平通过激活心脏型 K(ATP)通道诱导了强有力的心脏保护作用,药物结构中氟原子的存在带来了所有好处:更高的脂溶性、降低的毒性、氧化和热降解抗性、在体内代谢降低以及治疗作用延长。